Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gynaecological cancers

3750 - Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer


20 Oct 2018


Poster Discussion session - Gynaecological cancers


Clinical Research;  Immunotherapy

Tumour Site

Endometrial Cancer


Ana Oaknin


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


A. Oaknin1, S.L. Ellard2, C. Leath III3, V. Moreno4, R. Kristeleit5, W. Guo6, S. Lu7, D. Jenkins8, K. McEachern8, K. Yu Jen9, S. Dunlap9, E. Im10, L. Gilbert11

Author affiliations

  • 1 Medical Oncology, Vall d’Hebron University Hospital; Vall d’Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 Medical Oncology, British Columbia Cancer Agency and University of British Columbia, V1Y 5L3 - Vancouver/CA
  • 3 Obstetrics & Oncology, University of Alabama at Birmingham, Birmingham/US
  • 4 Medical Oncology, START MADRID-FJD, Hospital Fundacion Jimenez Diaz, 28040 - Madrid/ES
  • 5 Oncology, University College London UCL Cancer Institute, WC1E 6DD - London/GB
  • 6 Biostatistics, TESARO, Inc., Waltham/US
  • 7 Clinical Pharmacology, TESARO, Inc., Waltham/US
  • 8 Translational Research, TESARO, Inc., Waltham/US
  • 9 Clinical Science, TESARO, Inc., Waltham/US
  • 10 Oncology Clinical research, TESARO, Inc., Waltham/US
  • 11 Obstetrics And Gynecology, McGill University Health Centre, Montreal/CA

Abstract 3750


TSR-042, a humanized monoclonal antibody, targets programmed death (PD)–1 effectively blocking interaction with its ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase 1 GARNET trial (NCT02715284).1 We present safety and efficacy data from the microsatellite instability-high (MSI-H) endometrial cancer (EC) cohort, pharmacokinetics (PK) and receptor occupancy (RO) at the recommended phase 2 dose (RP2D), as well as biomarker analyses.


Patients with previously treated MSI-H EC were evaluated. Patients received the RP2D of TSR-042: 500 mg Q3W for the first 4 cycles and 1000 mg Q6W thereafter. Antitumor activity was assessed by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Serum and peripheral blood mononuclear cells were collected for PK and RO measurements, respectively.1


Twenty-five patients with MSI-H EC were enrolled and treated; median age was 66 years old and 56% had received prior therapy for metastatic/recurrent disease (median=1.0 line of treatment). Seventeen patients had at least 1 tumor assessment (week 12) and also underwent biomarker profiling. Partial responses (confirmed and unconfirmed) occurred in 9 patients (53%), 1 (6%) had stable disease, and 6 (35%) had progressive disease; one patient was not evaluable. Duration of response data for this cohort is not mature yet. Of the 25 patients, 18 (72%) had ≥1 adverse event (AE) with grade ≥3 AEs reported in 11 patients (44%). Treatment-emergent AEs (TEAEs) occurred in 18 patients (72%) with grade ≥3 TEAEs in 1 patient (4%) who experienced grade ≥3 leukopenia and grade ≥3 neutropenia. TSR-042 PK was dose-proportional. Maximal RO was observed at RP2D consistent with results in Parts 1 and 2A.1


TSR-042 demonstrated robust clinical activity in patients with previously treated recurrent or advanced MSI-H EC and an acceptable toxicity profile. PK was consistent across patients. Maximal RO was attained at RP2D. 1. Sachdev JC et al. Ann Oncol. 2017(suppl 5):28:420;1185P.

Clinical trial identification


Legal entity responsible for the study

Tesaro, Inc.


Tesaro, Inc.

Editorial Acknowledgement

Editorial support, funded by Tesaro, Inc. (Waltham, MA, USA) and coordinated by Ted Paunescu, PhD of Tesaro, Inc., was provided by Dena McWain of Ashfield Healthcare Communications (Middletown, CT, USA).


A. Oaknin: Advisory boards: Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro, Inc.; Support for travel or accommodation: Roche, AstraZeneca, PharmaMar. S.L. Ellard: Advisory boards: AstraZeneca, Astellas; Honoraria: AstraZeneca. C. Leath, III: Advisory boards: Mateon, Celsion. W. Guo, S. Lu, D. Jenkins, K. McEachern, K. Yu Jen, S. Dunlap, E. Im: Employment and stock and other ownership interests: Tesaro, Inc. L. Gilbert: Advisory boards: AstraZeneca, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.